Besides, Teva has nonsubstitutable Advair drug-device copy AirDuo RespiClick and its authorized generic on the market, plus other would-be Advair copycats from Novartis' Sandoz and a partnership between Hikma and Vectura could return from FDA exile. RELATED: Mylan and Pfizer report new issues affecting some EpiPens that can delay treatment It's no surprise, then, that Mylan tried Monay to divert attention away from the Advair copy, dubbed Wixela, to other products. "Our ability to deliver long-term growth is not dependent upon the timing of any one approval, any one country's market dynamics or any one dosage form, but rather the broader, more complete context of Mylan's global diversified business model," said CEO Heather Bresch on the Monday call.